Clinical Trial Update: A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy [Phase 3]

View source ↗

Summary

Phase 3 study of Deramiocel (CAP-1002) in ambulatory and non-ambulatory Duchenne muscular dystrophy patients is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Deramiocel (CAP-1002)

Snippet

Sponsor: Capricor Inc. | Conditions: Muscular Dystrophies, Muscular Dystrophy, Duchenne | Phase 3 | Status: ACTIVE_NOT_RECRUITING